Selected article for: "lobectomy lung and lung cancer"
Author: Song, Seung Won; Yoo, Kyung Yeon; Ro, Yong Sung; Pyeon, Taehee; Bae, Hong-Beom; Kim, Joungmin
Title: Sugammadex is associated with shorter hospital length of stay after open lobectomy for lung cancer: a retrospective observational study
  • Cord-id: 76lqsg38
  • Document date: 2021_3_23
    • ID: 76lqsg38
    Snippet: BACKGROUND: Sugammadex is associated with few postoperative complications. Postoperative pulmonary complications (PPC) are related to prolonged hospitalizations. Present study explored whether the use of sugammadex could reduce PPCs and thereby reduce hospital length of stay (LOS) after lung surgery. METHODS: We reviewed the medical records of patients who underwent elective open lobectomy for lung cancer from January 2010 to December 2015. Patients were divided into the sugammadex group and pyr
    Document: BACKGROUND: Sugammadex is associated with few postoperative complications. Postoperative pulmonary complications (PPC) are related to prolonged hospitalizations. Present study explored whether the use of sugammadex could reduce PPCs and thereby reduce hospital length of stay (LOS) after lung surgery. METHODS: We reviewed the medical records of patients who underwent elective open lobectomy for lung cancer from January 2010 to December 2015. Patients were divided into the sugammadex group and pyridostigmine group. The primary outcome was hospital LOS and secondary outcomes were postoperative complications and overall survival at 1 year. The cohort was subdivided into patients with and without prolonged LOS to explore the effects of sugammadex on outcomes in each group. Risk factors for LOS were determined via multivariate analyses. After propensity score matching, 127 patients were assigned to each group. RESULTS: Median hospital LOS was shorter (10.0 vs. 12.0 days) and the incidence of postoperative atelectasis was lower (18.1 vs. 29.9%) in the sugammadex group. However, no significant difference in overall survival between the groups was seen over 1 year (hazard ratio, 0.967; 95% confidence interval, 0.363 to 2.577). Sugammadex was a predictor related to LOS (exponential coefficient 0.88; 95% CI 0.82–0.95). CONCLUSIONS: Our data suggest that sugammadex is a preferable agent for neuromuscular blockade (NMB) reversal than cholinesterase inhibitors in this patient population. TRIAL REGISTRATION: This study registered in the Clinical Research Information Service of the Korea National Institute of Health (approval number: KCT0004735, Date of registration: 21 January 2020, Retrospectively registered).

    Search related documents:
    Co phrase search for related documents
    • abdominal surgery and acute respiratory distress syndrome: 1, 2, 3, 4
    • abdominal surgery and acute respiratory failure: 1, 2, 3, 4, 5, 6, 7
    • abdominal surgery and additional analysis: 1
    • abdominal surgery and logistic model: 1, 2
    • abdominal surgery and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • accessory muscle and acute respiratory failure: 1
    • acute respiratory distress syndrome and additional analysis: 1, 2, 3, 4
    • acute respiratory distress syndrome and admission period: 1, 2, 3
    • acute respiratory distress syndrome and log rank test compare: 1
    • acute respiratory distress syndrome and logistic model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory failure and admission period: 1, 2, 3, 4
    • acute respiratory failure and log rank test compare: 1
    • acute respiratory failure and logistic model: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory failure and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • additional analysis and logistic model: 1, 2, 3, 4, 5
    • additional analysis and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • admission period and logistic model: 1
    • admission period and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16